
Novel strategy targets chronic liver diseases
The approach published in Nature Cancer leads to a cell-toxic accumulation of saturated fatty acids that drives tumour cells into apoptosis. HCC...

Abingworth raises US-$465m for new life sciences fund
UK-US venture capitalist Abingworth yesterday announced the final closing of its 13th life sciences venture fund, ABV 8, at US$465m exceeding...

Record year for Swiss biotech industry
Driven by the corona crisis, the Swiss biotech ecosystem is thriving as never before. This is evidenced by the Swiss Biotech Report from EY, the...

COVID-19: Study finds neutralising antibodies to disappear rapidly
According to the “Rhineland population-based Study”, published by researchers under Prof. Monique Breteler at the DZNE in Bonn, Germany blood...

InteRNA Technologies secures €18.5m in Series B financing
Waterman Ventures and current shareholders Aglaia Oncology Funds and OostNL participated in the funding. The Utrecht-based...

EMA: AZD1222 causes serious rare ADEs
However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...